Age‐Specific Effectiveness of Antiviral Agents on the Secondary Household Transmission of Influenza

Abstract

Objectives: We investigate the effects of age, vaccination history, treatment timing, and type of antiviral agent in index cases and household members on the risk of influenza transmission.

Methods: We conducted a retrospective household survey in Japan between October 2018 and February 2019, enrolling 915 households (3248 members) with influenza cases. Secondary attack rates (SARs) and odds ratios (ORs) were calculated for subgroups stratified by treatment timing, antiviral agent, and age group.

Results: When treatment was initiated within 48 hours of symptom onset, both index cases and household contacts aged 0–14 and 15–50 years exhibited significantly higher odds of household transmission compared with those aged 51 years and older. Early treatment was associated with lower odds of transmission, with Baloxavir (OR = 0.74, 95% CI: 0.57–0.96) and Laninamivir (OR = 0.57, 95% CI: 0.41–0.79) showing lower ORs than Oseltamivir.

Conclusions: Our findings highlight that both clinical and demographic factors substantially influence household influenza transmission. Early initiation of antiviral treatment, combined with the use of Baloxavir or Laninamivir, significantly reduces the risk of secondary transmission, particularly in younger populations who play a central role in household spread.

Multivalent antiviral conjugates enhance activity against Influenza via cross-linking viruses
Xun Feng, Lunzhi Yuan, Lei Zhao +11
Nature Communications4 Oct 2026Peer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMC
Repositioning antiviral phytoconstituents as broad-spectrum inhibitors of influenza A neuraminidase and human metapneumovirus fusion protein
Nouh Mounadi, Hassan Nour, M’hammed El Kouali +2
PLOS One2 Sep 2026Peer-reviewedCC BY 4.0Full textPharmacology & toxicologyPLOS
Tumour Cell-Associated Heterogeneity in Antiviral Immunity Shapes Influenza Responses and Immune-Modulatory Signalling in Lung Cancer
Mark A. Miles, Isabella Rosano, Stella Liong +4
Cancers30 Oct 2026Peer-reviewedCC BY 4.0OncologyCrossref
Out-of-pocket costs and productivity losses associated with influenza illness and caregiving in a household study in the United States, 2024-2025
E. B. White, J. Pike, C. Y. Vargas +15
medRxiv10 Sep 2026PreprintCC0Full textEpidemiology & public healthmedRxiv
Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2
Blandine Padey, Clément Droillard, Victoria Dulière +10
Antiviral Research5 Oct 2026Peer-reviewedCC BY 4.0Full text5 citedMicrobiology Infectious diseaseHAL

Cite

BibTeX RIS

BibTeX

@article{seo2026agespecific,
  title = {{Age‐Specific Effectiveness of Antiviral Agents on the Secondary Household Transmission of Influenza}},
  author = {Jeonghwa Seo and Jihyeon Kim and Hiroshi Nishiura and Hyojung Lee},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  month = oct,
  doi = {10.1111/irv.70337},
  url = {https://doi.org/10.1111/irv.70337},
  note = {CC BY-NC-ND 4.0},
}

RIS

TY  - JOUR
TI  - Age‐Specific Effectiveness of Antiviral Agents on the Secondary Household Transmission of Influenza
AU  - Jeonghwa Seo
AU  - Jihyeon Kim
AU  - Hiroshi Nishiura
AU  - Hyojung Lee
PY  - 2026
DA  - 2026/10/27
JO  - Influenza and Other Respiratory Viruses
DO  - 10.1111/irv.70337
UR  - https://doi.org/10.1111/irv.70337
AB  - Objectives: We investigate the effects of age, vaccination history, treatment timing, and type of antiviral agent in index cases and household members on the risk of influenza transmission.  Methods: We conducted a retrospective household survey in Japan between October 2018 and February 2019, enrolling 915 households (3248 members) with influenza cases. Secondary attack rates (SARs) and odds ratios (ORs) were calculated for subgroups stratified by treatment timing, antiviral agent, and age group.  Results: When treatment was initiated within 48 hours of symptom onset, both index cases and household contacts aged 0–14 and 15–50 years exhibited significantly higher odds of household transmission compared with those aged 51 years and older. Early treatment was associated with lower odds of transmission, with Baloxavir (OR = 0.74, 95% CI: 0.57–0.96) and Laninamivir (OR = 0.57, 95% CI: 0.41–0.79) showing lower ORs than Oseltamivir.  Conclusions: Our findings highlight that both clinical and demographic factors substantially influence household influenza transmission. Early initiation of antiviral treatment, combined with the use of Baloxavir or Laninamivir, significantly reduces the risk of secondary transmission, particularly in younger populations who play a central role in household spread.
SN  - 1750-2640
SN  - 1750-2659
ER  -

Abstract

Related

Cite